The clinical trial, sponsored by China National Biotec Group Company Limited, aims to evaluate the immunogenicity, safety, and antibody persistence of a third booster dose of an inactivated SARS-CoV-2 vaccine in older patients with hypertension and/or diabetes. This demographic is particularly vulnerable to severe COVID-19 outcomes, thus presenting a significant market opportunity for booster vaccinations targeting this population. The trial's findings could enhance the vaccine's market positioning, especially in regions with high prevalence of these comorbidities. Competitive implications include the need for differentiation from other COVID-19 vaccines and boosters currently available, particularly those from Western pharmaceutical companies. Diligence considerations should focus on regulatory compliance, safety data, and the potential for expanded use in similar patient populations.